Binding of anti-glycoprotein IIb/IIIa and anti-glycoprotein Ib monoclonal antibodies to platelets did not differ significantly between the hypertensive patients and controls, but platelet ...

12 Besides glycoprotein Ib, several collagen receptors ... However, the transient incomplete blockade of platelet COX-1 and of glycoprotein IIb/IIIa by some traditional nonsteroidal ...

The platelet integrin receptor α IIb β 3 (GPIIb/IIIa) plays a critical role in thrombosis and hemostasis by mediating interactions between platelets and several ligands, primarily fibrinogen.

GP IIb/IIIa antagonists are potent inhibitors of platelet aggregation. A clear understanding of the bleeding risks associated with their use is of particular importance in the cardiac ...

The αIIbβ3 integrin, also known as the platelet fibrinogen receptor or GP IIb-IIIa, has been the focus of an entire class of blood-thinning drugs, called GPIIb-IIIa agonists. The Penn ...

The epitopes targeted by these antibodies usually reside on glycoprotein IIb/IIIa or Ib/V/IX complexes, the major platelet receptors for fibrinogen and von Willebrand factor, respectively.

The participation of platelets in atherogenesis and the subsequent ... on the modulation of soluble ligand binding to integrin-α IIb β 3. Secretion leads to the release of granule components ...

RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...

The most common etiology of pseudothrombocytopenia is platelet clumping induced by EDTA, which is the anticoagulant present in the purple tube in which blood is collected for a CBC. This clumping ...

for patients who were candidates for radical resection with clinical stage IB, II, and IIIA NSCLC. Chemotherapy- and radiotherapy-naive patients were required to have stage I (except for T1N0), II, or ...

Methods: The LUN19-396 is a phase II biomarker study that enrolls pts with resected NSCLC stage IB (tumors ≥ 4cm), IIA, IIB, and select IIIA (T3N1-2, T4N0-2). The ctDNA will be assessed within 60 days ...